Experimental Obesity Drug Showed Early Potential
New laboratory data suggests an oral drug candidate could offer an alternative to common injectable weight-loss treatments.
Updated on Sept. 29, 2026 in Diabetes
Live Poll
Do you believe new pharmaceutical weight loss options will offer reliable alternatives to existing treatments?
Verdiva Bio presented preliminary laboratory findings on its investigational drug, VRB-103, an oral amylin peptide analog for obesity treatment. The drug is currently being tested in early-stage human clinical trials.
Why it matters
Researchers are exploring amylin agonism as a distinct mechanism to help patients who do not respond to existing GLP-1 therapies. This study suggests a potential new path for obesity management that does not rely on the standard incretin-based approach.
In vitro testing demonstrated that the experimental drug VRB-103 has high potency and selectivity across three human amylin receptor subtypes compared to current benchmark therapies. These findings are preliminary, as the drug is currently in a Phase 1 study to evaluate its safety profile.
The players
Verdiva Bio
A pharmaceutical company currently developing oral peptide analogs for metabolic conditions.
The details
VRB-103 is designed to be selective for human amylin receptors 1 and 3 while minimizing activity at the human calcitonin receptor to reduce potential side effects. The manufacturer utilizes a proprietary oral absorption enhancer technology to enable the delivery of these peptide analogs, which typically require injection. By targeting amylin, the drug aims to mimic natural appetite-regulating hormones through a non-incretin pathway.
Timeline
September 28-October 2, 2026: The 62nd EASD Annual Meeting took place in Milan, Italy.
End of 2026: Initial results from the Phase 1 trial of VRB-103 are expected.
Health Landscape
The development of VRB-103 sits within a broader scientific effort to expand the toolkit for weight management beyond the current dominance of GLP-1 receptor agonists. Presenting these findings at the 62nd EASD Annual Meeting underscores the increasing focus on non-incretin pathways.
Because this drug is still in early-stage trials, it is not available for clinical use or prescription. Those interested in emerging treatment options for obesity should consult with their physician to understand what therapies are currently approved and accessible.
The takeaway
While VRB-103 represents a novel approach to weight loss, it remains an experimental treatment with no proven clinical benefit in humans to date. Keep track of updates on clinical trial registries if you are interested in how non-GLP-1 therapies evolve for metabolic conditions.
What happens next
Initial data from the Phase 1 clinical study of VRB-103 is anticipated by the end of 2026.
Further reading
You can find more background on current research developments by visiting our Diabetes section.
More information
For more information on the company's research pipeline, visit the Verdiva Bio company website.
Live Poll
Do you believe new pharmaceutical weight loss options will offer reliable alternatives to existing treatments?
